Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec 1;208(11):1249-1250.
doi: 10.1164/rccm.202309-1622LE.

Reply to Yasuma et al

Affiliations
Comment

Reply to Yasuma et al

Allison E Norlander et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effect of the prostaglandin I2 analogues epoprostenol or treprostinil on (A) T regulatory cell (Treg) (Foxp3+CD4+) percentage, (B) Foxp3 mean fluorescence intensity in Tregs, (C) CD44 mean fluorescence intensity in Tregs, and (D) ratio of T effector cells (CD4+Foxp3) to Tregs (CD4+Foxp3+). Analysis was performed with a paired t test. *P < 0.05. MFI = mean fluorescence intensity; PGI2 = prostaglandin I2.

Comment on

References

    1. Norlander AE, Abney M, Cephus JY, Roe CE, Irish JM, Shelburne NJ, et al. Prostaglandin I2 therapy promotes regulatory T cell generation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med . 2023;208:737–739. - PMC - PubMed
    1. Greig SL, Scott LJ, Plosker GL. Epoprostenol (Veletri®, Caripul®): a review of its use in patients with pulmonary arterial hypertension. Am J Cardiovasc Drugs . 2014;14:463–470. - PubMed
    1. Kumar P, Thudium E, Laliberte K, Zaccardelli D, Nelsen A. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet . 2016;55:1495–1505. - PMC - PubMed

LinkOut - more resources